- Report
- February 2025
- 218 Pages
Global
From €4501EUR$4,799USD£3,871GBP
- Report
- October 2024
- 181 Pages
Global
From €3325EUR$3,545USD£2,859GBP
€3694EUR$3,939USD£3,177GBP
- Report
- April 2025
- 196 Pages
Global
From €4643EUR$4,950USD£3,993GBP
- Report
- September 2024
- 175 Pages
Global
From €4690EUR$5,000USD£4,033GBP
- Report
- March 2025
- 200 Pages
Global
From €4211EUR$4,490USD£3,622GBP
- Report
- August 2024
- 175 Pages
Global
From €4690EUR$5,000USD£4,033GBP
- Report
- June 2024
- 183 Pages
Global
From €4221EUR$4,500USD£3,630GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2814EUR$3,000USD£2,420GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
India
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
North America
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
Germany
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
Italy
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
Oman
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
France
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4455EUR$4,750USD£3,831GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4455EUR$4,750USD£3,831GBP

Exenatide is a drug used to treat endocrine and metabolic disorders. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to regulate glucose levels in the body. Exenatide is used to treat type 2 diabetes, and is administered as a subcutaneous injection. It works by stimulating the release of insulin from the pancreas, and by slowing the rate of glucose absorption from the gastrointestinal tract.
Exenatide is available in two forms: a long-acting version (Bydureon) and a short-acting version (Byetta). Both versions are used to improve glycemic control in adults with type 2 diabetes, and can be used in combination with other diabetes medications. Exenatide has been shown to reduce the risk of cardiovascular events in patients with type 2 diabetes.
Exenatide is marketed by several companies, including AstraZeneca, Eli Lilly, and Novo Nordisk. It is also available as a generic drug in some countries. Show Less Read more